结核病与肺部健康杂志 ›› 2015, Vol. 4 ›› Issue (4): 223-227.doi: 10.3969/j.issn.2095-3755.2015.04.004

• 论著 • 上一篇    下一篇

肺结核患者介入与非介入治疗药物不良反应的研究

黄义欢,陈伟生,陈镇强   

  1. 515073,广东省汕头市第三人民医院
  • 收稿日期:2015-11-10 出版日期:2015-12-30 发布日期:2015-12-30
  • 通信作者: 陈伟生,Email:stchenws@163.com

Study on adverse drug reactions of interventional and non-interventional therapy for pulmonary tuberculosis

HUANG Yi-huan, CHEN Wei-sheng, CHEN Zhen-qiang   

  1. The Third People’s Hospital, Shantou City, Guangdong, Shantou 515073,China
  • Received:2015-11-10 Online:2015-12-30 Published:2015-12-30
  • Contact: CHEN Wei-sheng,Email:stchenws@163.com

摘要: 目的通过监测肺结核介入治疗药物不良反应的发生情况,评估肺结核介入治疗的临床意义。方法 于2014年1月1日至2015年6月30日,选取广东省汕头市第三人民医院内科二病区收住的年龄14岁以上,无肝、肾、心、眼功能障碍的肺结核患者作为研究对象,共286例。收集患者病历信息,并按治疗方式分为介入组(167例)和非介入组(119例)。观察各组研究对象在2个月的治疗期间,药物不良反应的发生情况。结果286例肺结核患者不良反应发生率为35.3%(101/286)。介入组和非介入组药物不良反应发生率分别为37.7%(63/167)和31.9%(38/119),差异无统计学意义(χ2=1.02,P>0.05);两组间男性[27.5%(46/167)、23.5%(28/119)]女性[10.2%(17/167)、8.4%(10/119)]、有[9.0%(15/167)、9.2%(11/119)]无[28.7%(48/167)、22.7%(27/119)]饮酒史、有[6.0%(10/167)、4.2%(5/119)]无[31.7%(53/167)、27.7%(33/119)]糖尿病史者药物不良反应发生率差异均无统计学意义(χ2值分别为0.00、0.33、0.61,P值均>0.05); 治疗1、2、3周药物不良反应发生率介入组分别为4.2%(7/167)、6.0%(10/167)、6.6%(11/167);非介入组分别为5.0%(6/119)、10.1%(12/119)、6.7%(8/119),差异均无统计学意义(χ2值分别为0.12、1.64、0.00,P值均>0.05)。介入组肝功能异常和轻度肝损伤、中度及以上肝损伤发生率分别为15.6%(26例)、3.0%(5例);非介入组分别为10.1%(12例)、5.0%(6例),中度及以上肝损伤发生率低于肝功能异常和轻度肝损伤的发生率(χ2=16.27,P<0.01)。结论临床介入治疗没有明显增加药物不良反应的发生率。

Abstract: Objective To evaluate the clinical significance of interventional therapy for pulmonary tuberculosis (PTB) through monitoring the occurrence of the adverse drug reactions of the therapy.Methods 286 PTB patients who were over the age of 14 and had no dysfunction in liver, kidney, heart and eyes, hospitalized in the Third People’s Hospital of Shantou from Jan. 1st, 2014 to Jun. 30th, 2015 were enrolled. The patients were divided into intervention group (167 cases) and non-intervention group (119 cases) according to their treatment methods after collecting the information of their medical records. The adverse reactions of these two groups were observed in the two-month therapy.Results The adverse reaction rate of the 286 patients was 35.3% (101/286). It was 37.7% (63/167) for the intervention group and 31.9% (38/119) for the non-intervention group respectively. There was no statistically significant difference between these two groups (χ2=1.02, P>0.05). Additionally, after comparing the adverse reaction rates of the patients with different gender (male: 27.5% (46/167) and 23.5% (28/119); female:10.2% (17/167) and 8.4% (10/119)), history of alcohol intake (yes: 9.0% (15/167) and 9.2% (11/119); no: 28.7% (48/167) and 22.7% (27/119)), history of diabetes (yes: 6.0% (10/167) and 4.2% (5/119); no: 31.7% (53/167) and 27.7% (33/119)) in the two groups, there was no statistically significant difference (χ2=0.00, 0.33 and 0.61, all P values >0.05). The adverse drug reaction rates of the intervention group treated for 1 week, 2 weeks and 3 weeks were 4.2% (7/167), 6.0% (10/167) and 6.6% (11/167) respectively while those in non-intervention group were 5.0% (6/119), 10.1% (12/119) and 6.7% (8/119), with no statistical significance (χ2=0.12,1.64 and 0.00, all P values >0.05). The incidence rates of hepatic dysfunction and light hepatic injury, moderate and more serious hepatic injury were 15.6% (26 cases) and 3.0% (5 cases) for the intervention group, while those were 10.1% (12 cases) and 5.0% (6 cases) for the control group. The incidence rate of moderate and more serious moderate hepatic injury was significantly lower that of hepatic dysfunction and light hepatic injury (χ2=16.27, P<0.01).Conclusion Clinical interventional therapy do not apparently increase the incidence of adverse drug reactions.